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Abstract
Background and aims—Aging is associated with significant losses of skeletal muscle mass
and function. Numerous biochemical molecules have been implicated in the development of these
age-related changes, however evidence from human models is sparse. Assessment of transcript
expression is useful as it requires minimal tissue and may potentially be used in clinical trials. This
study aimed to compare mRNA expression of proteolytic genes in skeletal muscle of young (18–
35 yrs) and older (55–75 yrs) men.
Methods—Muscle tissue was obtained from young (n=14, 21.35±1.03 yrs) and older (n=13,
63.85±1.83 yrs) men using percutaneous biopsy, and transcript expression was quantified using
real-time polymerase chain reaction. Lower limb muscle mass was assessed using DEXA while
concentric peak torque (PT) and power were assessed via isokinetic dynamometer. When age-
related differences in mRNA expression were observed, Pearson correlation coefficients were
obtained to examine the relationship of transcripts to muscle mass and function.
Results—Older muscle contained significantly more transcript for Forkhead Box O 1 (FoxO1,
p=0.001), Inhibitor of DNA binding 1 (ID1, p=0.009), and Inhibitor of DNA Binding 3 (ID3,
p=0.043) than young muscle. FoxO1 was significantly correlated with lean mass (R=−0.44,
p=0.023) and PT (R=−0.40, p=0.046) while ID3 was significantly correlated with PT (R=−0.58,
p=0.001) and power (R=−0.65, p<0.001). Moreover, ID1 was significantly correlated with all
assessed measures of muscle function - mass (R=−0.39, p=0.046), PT (R=−0.53, p=0.005), and
power (R=−0.520, p=0.005).
Conclusion—These data suggest that FoxO1, ID1, and ID3 are potentially useful as clinical
biomarkers of age-related muscle atrophy and dysfunction.
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Sarcopenia, the age-related loss of muscle mass and quality, is a major healthcare concern
for older adults. The condition is a primary contributor to declines in muscle function and
the development of disability (1, 2). As a consequence of such disability, many older
persons are unable to remain fully independent in carrying out their daily activities. Because
of the costs associated with caring for an individual with compromised function, sarcopenia
is also an important contributor to escalating healthcare costs. Moreover, the absolute costs
associated with sarcopenia are likely to rise sharply in the coming decades considering that
the total number of persons over 65 years is expected to double over the next 25 years (3).
Hence, additional knowledge of mechanisms underlying sarcopenia development is
necessary to advance prevention and treatment efforts that will improve the quality of life
for millions of older adults.
A number of cellular mechanisms are known to contribute to skeletal muscle atrophy, of
which those contributing to myofibrillar protein breakdown are among the best described.
These mechanisms include the ubiquitin-proteasome system (4–6), calcium-activated
proteases (calpains) (7–9), myostatin (10–12), and inhibitors of DNA binding (IDs) (13–15).
Upregulation of these regulators contributes to the loss of myofibrillar protein by either
active proteolysis (ubiquitin-proteasome and calpains) or through the repression of anabolic
signaling (myostatin and IDs).
Despite the availability of extensive mechanistic data regarding these systems, translational
studies demonstrating relationships of these biochemical indices to clinical measures of
muscle mass and force production are few. Moreover, these few published results are
somewhat equivocal regarding age-dependent differences in skeletal muscle expression of
transcripts relevant to loss myofibrillar protein. Indeed, previous studies have indicated
either increases or no change with increasing age in muscle content of mRNA encoding for
proteins such as myostatin (16, 17), muscle-specific ring finger 1 (MuRF1) (17–19) and
forkhead box O 3A (FoxO3A) (17, 19, 20). Thus, the objective of this investigation was to
analyze relevant transcript expression between young and older men and to test the
hypothesis that differentially-expressed mRNA are associated with clinical measures of
muscle mass and function.
METHODS
Data are from young and older healthy men who volunteered for the study. Inclusion/
exclusion criteria are detailed elsewhere (21). Briefly, men 1) were between either 18–30 or
55–75 years, 2) had a physically sedentary lifestyle (reported no regular physical activity
beyond light walking in past year), 3) did not smoke, and 4) were not currently receiving or
had not recently completed (within 6 months) androgen therapy. All participants provided
oral and written informed consent based on documents approved by the Institutional Review
Board of Baylor University according to the principles of the Declaration of Helsinki.
Body mass, heart rate, and blood pressure were determined by standard procedures. Body
composition was assessed using dual energy x-ray absorptiometry (DEXA) (Hologic,
Waltham, MA). Lean mass was recorded as g/cm2 in the lower limbs. Isokinetic muscle
function of the quadriceps extensors was assessed using a Biodex-System 3 dynamometer
(Biodex Medical Systems, Inc., Shirley, NY, USA). On a separate visit prior to data
collection, participants were familiarized to the tests to be completed. During data
collection, three submaximal and two maximal practice repetitions were completed with the
non-dominant limb prior to performing five maximal concentric contractions at 60 degrees/
second with a 75° range of motion. Peak torque (PT) and peak muscular power were
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recorded for the bout. Skeletal muscle biopsies were obtained under local anesthesia of 1%
Xylocaine from middle portion of the vastus lateralis muscle of the dominant limb at the
midpoint between the patella and the greater trochanter of the femur at a depth between 2–3
cm. After removal, tissue samples were immediately frozen in liquid nitrogen and then
stored at −80°C for future analyses.
Real-time polymerase chain reaction (RT-PCR) procedures were conducted as previously
described (22, 23). Briefly, 1) total RNA was isolated from muscle using TRI-reagent
(Sigma Chemical Co., St. Louis, MO), 2) cDNA was synthesized using the iScript cDNA
Synthesis Kit (Bio-Rad, Hercules, CA), 3) sense and anti-sense primers for target genes and
β-actin control were synthesized commercially (Integrated DNA Technologies, Coralville,
IA), and 4) RT-PCR was performed using the iCycler IQ Real-Time PCR Detection System
(Bio-Rad, Hercules, CA). The quantity of target gene mRNA was determined relative to the
expression of β-actin using the formula 2−ΔCT where ΔCT = CT target − CT β-actin as
previously reported in the literature (19, 24).
Data were initially analyzed for normality, homogeneity of variance, and potential outliers
prior to determining descriptive statistics. Because of the frequency of assumptions
violations, gene expression data for the groups were compared using the non-parametric
Mann-Whitney U test. For all other data, groups were compared using independent Student
t-tests. Pearson correlation coefficients were calculated to examine the relationships among
muscle mass, function, and differentially-expressed transcripts. All statistical procedures
were performed using SPSS 16.0 software (Chicago, IL) and a probability level of <0.05
was adopted throughout.
RESULTS
In the present study, we obtained biopsy samples from 14 young (21.35±1.03 yrs) and 13
older (63.85±1.83 yrs) men. The older group had a significantly greater body mass
(p=0.036) and body fat percentage p (<0.001) than the young group (Table 1). The young
group also displayed significantly greater lean mass (p=0.004), PT (p=0.004), and muscular
power (p=0.011) than older counterparts.
Expression of all target genes was higher in the older group, although the majority of these
differences did not reach significance (Table 1). However, older muscle demonstrated
significantly greater expression of mRNA for FoxO1 (p=0.001), ID1 (p=0.009), and ID3
(p=0.043) than did younger muscle (Figs. 1–3). Examination of the relationships of these
mRNA with muscle mass showed that muscle mass was significantly and inversely
correlated with expression of FoxO1 (R=−0.44, p=0.023) and ID1 (R=−0.39, p=0.046). The
correlations of ID1 (R=−0.520, p=0.005) and ID3 (R=−0.65, p<0.001), but not FoxO1, were
significantly correlated with muscle power. Finally, PT was significantly and inversely
correlated with all three of the differentially expressed mRNA (FoxO1: R=−0.40, p=0.038;
ID1: R=−0.53, p=0.005; ID3: R=−0.58, p=0.001).
DISCUSSION
The present study shows that skeletal muscle gene expression of FoxO1, ID1, and ID3 is
significantly greater in older men than younger counterparts. To our knowledge, this is the
first investigation to demonstrate age-related differences in these transcripts in humans.
Furthermore, this is the first study to report that expressions of these differentially-expressed
transcripts are associated with clinical indices of skeletal muscle mass and function.
FoxO is a family of transcription factors that has been implicated in the development of
skeletal muscle atrophy through the ubiquitin-proteasome system (25, 26). Within skeletal
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muscle, FoxO family members signal increases in ubiquitin-proteasome-mediated
proteolysis by up-regulation of muscle specific E3 ligases, including MuRF1 and muscle
atrophy F box (MAFbx/Atrogin1) (25). Furthermore, FoxO members also appear to play a
role in lysosomal autophagy (26, 27) and may also regulate the expression of myostatin (28).
To our knowledge, no published studies have reported age-related increases in gene
expression of FoxO1 in humans. Previous investigations have however indicated that
mRNA expression of FoxO3A is either elevated (19, 20) or unchanged (17) in sedentary
older individuals. The present data concur with the latter finding as we did not observe
significant differences in FoxO3A expression between groups. Further study is needed to
clarify the nature of this discrepancy. We suspect that the strong up-regulation of FoxO1
may play some role in ameliorating changes in FoxO3A, but more investigation is certainly
required to address this speculation.
Interestingly, despite the presence of significantly greater FoxO1 transcript in older muscle,
no significant difference was observed between groups for either MurF1 or Atrogin1. Our
findings are intriguing as these FoxO family members are most often ascribed the function
of acting on these atrogenes. Several options thus exist for the potential role of FoxO1 in
human muscle. First, the lack of group differences for the atrogenes could suggest that
FoxO1 may be acting primarily through autophagic mechanisms. Second, because a weak
trend was observed between groups for MuRF1, one could speculate that a larger sample
size would reveal a significant difference in MuRF1 and that this difference is mediated by
FoxO1. This possibility appears plausible despite the striking similarity in Atrogin1 mRNA
as accumulating evidence suggests that these two ubiqutin-ligases are regulated in distinct,
independent manners (29). However, this potential difference in MuRF1 could also stem
from age-dependent increases in NF-kB signaling (21) as NF-kB signals MuRF1 activation
(30, 31). Much work remains to be done in elucidating the complexity of these signaling
pathways in humans.
In addition to the age-related increase in FoxO1 gene expression, we also observed
significant increases in ID family members 1 and 3 with no significant difference observed
for ID2. At present, little information exists to indicate what molecular differences may
regulate ID1 and ID3 differently than ID2 in human muscle during the aging process. IDs
are basic helix-loop-helix proteins that act as negative regulators of myogenic regulatory
factors (MRFs) by preventing the initiation of transcription by forming MRF-ID
heterodimers that are unable to bind to E boxes because they lack a DNA binding region
(13, 32). Controlled expression of IDs is critical for maintenance of muscle mass as they are
critical repressors of satellite cell differentiation (15, 33) and may contribute to apoptosis of
myonuclei (13). Previously, Alway et al. (14) reported that ID mRNA levels were ~300–
900% higher in skeletal muscle from old rats as compared to young; however this is the first
study to report age-related increases in ID expression in humans. Future studies should
examine not only ID expression in conjunction with aging, but that of the associated MRFs
to determine which of these anabolic signals is most targeted by the IDs in older humans.
Several caveats should be noted to interpret the results of this study. First, the results may
not be applicable to women as only men were included in the study. Second, due to its cross-
sectional nature, this study is not able to determine if skeletal muscle expression of these
genes causes declines in skeletal muscle atrophy and/or function. Finally, many other
mechanisms, including alterations in cellular signaling of anabolism and satellite cell
proliferation, likely contribute to age-related changes in muscle mass and function. As such,
this investigation represents but a small step in delineating potential signals of muscle
dysfunction in humans. Still, this study is the first to report elevated gene expression of
FoxO1, ID1, and ID3 in older men and associations of these mRNA with clinical measures
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of muscle mass and function. Although further study is needed, these indices may represent
clinically-relevant signals of potential muscle dysfunction in advanced age.
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mRNA expression of FoxO1 in young and older men. Gene expression expressed relative to
β-actin according to 2−ΔCT where ΔCT = CT target − CT β-actin. Bars depict means, error
bars reflect standard error.
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mRNA expression of ID1 in young and older men. Gene expression expressed relative to β-
actin according to 2−ΔCT where ΔCT= CT target − CT β-actin. Bars depict means, error
bars reflect standard error.
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mRNA expression of ID3 in young and older men. Gene expression expressed relative to β-
actin according to 2−ΔCT where ΔCT= CT target − CT β-actin. Bars depict means, error
bars reflect standard error.
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Table 1
Physical characteristics, body composition, muscle function, and muscle expression of atrophy-related genes.
Young (n=14) Older (n=13) p-value
 Height (cm) 176.8±1.6 174.0±1.7 0.225
 Body mass (kg) 79.6±4.6* 93.7±4.2* 0.036
 Body fat % 21.0±2.1* 31.7±1.2* <0.001
 Lower limb lean mass (g/cm2) 24.9±0.7* 22.0±0.6* 0.004
 Quadriceps peak torque (Nm) 149.6±7.1* 115.3±8.5* 0.004
 Quadriceps power (W) 94.9±7.0* 67.6±7.1* 0.011
Muscle gene expressiona
 MuRF 1 0.32±0.66 0.84±0.30 0.089
 Atrogin 1 14.84±5.67 16.55±4.29 0.356
 FoxO3A 0.41±0.09 1.09±0.53 0.451
 Calpain 1 1.14±0.23 2.12±0.58 0.065
 Calpain 2 1.22±0.29 3.01±1.56 0.527
 Myostatin 0.59±0.12 1.83±0.85 0.650
 ID2 0.28±0.05 0.41±0.12 0.771
Values are means±SE.
*p<0.05 significantly different between groups.
aAll gene expression values expressed relative to β-actin according to 2−ΔCT where ΔCT= CT target − CT β-actin.
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